

A NEW BIOLOGICAL SCREENING SYSTEM FOR LOCAL ANAESTHETICS BY INHIBITION MOBILITY OF *TETRAHYMENA PYRIFORMIS*

D. AL-SAAFI* AND W.E. SNEADER**

From the* School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Islamic Republic of Iran, and the
** School of Pharmacy and Pharmacology, University of Strathclyde, Glasgow, Scotland.

ABSTRACT

An alternative *in vitro* approach to drug screening has been the use of human cell cultures for antiviral agents and microbial cell cultures for the assessment of the carcinogenic potential of selected compounds. A number of protozoan species have been also used as drug screens for anti-protozoal agents. The ciliated protozoan *Tetrahymena pyriformis* species has been widely utilised as a drug screen for a variety of pharmacologically active agents.

Accordingly, it was decided to investigate whether *T. pyriformis* could be used as a preliminary drug screen for evaluation of the local anaesthetic activity and duration of action of certain commercially available local anaesthetics. In this communication, the results of this new *in vitro* biological drug screen are reported. It is based on the complete protozoan cell immobilisation by the anaesthetic solution. A positive inverse correlation was observed between the lowest concentration (minimum inhibitory concentration=MIC) that wholly inhibits the mobility of all cells of *T. pyriformis* and the duration of action of the test compounds. Generally, MIC was high for the short-acting anaesthetics and low for the long-acting ones. The results suggest the suitability of this new microbiological assay system for the evaluation of local anaesthetic activity and duration of action and possibly irritancy and toxicity of other local anaesthetics as well as potentially active therapeutic agents which possess surface activity.

MJIRI, Vol. 6, No. 1, 55-58, 1992

INTRODUCTION

The ciliated protozoan *T. pyriformis* species has been used as an alternative *in vitro* drug screen to evaluate a number of biologically active substances such as antiprotozoals¹, antitumor agents,²⁻¹¹ antihormones,^{12,13} antimicrobials,¹⁴ antimalarials,¹⁵ antihistamines,¹⁶ antipsychotics,^{17,18} antivitamin,¹⁹ hypocholesterimics,^{20,21} inhalational anaesthetics,²²

and others.²³⁻³⁰ Nandini-Kishore, et al³¹ and Thompson, et al^{32,33} have suggested the usefulness of *T. pyriformis* cell as a model system for membrane studies. There is a pronounced difference in lipid composition among the cell's various functionally distinct membrane systems which gives a significant lipid specificity to the membrane sites. In an effort to develop new *in vitro* biological assay method to evaluate local anaesthetics, this investigation has been initiated. *T. pyriformis* species was used as a preliminary microbiological system for screening the local anaesthetic activity and duration of action of five commonly clinically em-

* Presented at the 1st Seminar on Iranian Self-Sufficiency of Pharmaceutical Industries, Tehran, Iran, 1988.

ployed local anaesthetic agents. It is based on the examination of the complete immobilisation of whole *T. pyriformis* cells in the sample by the assayed compound. The results of this study are reported in this communication.

METHODS

Three-day old *T. pyriformis* cells (GL Strain) maintained in an unshaken axenic culture at room temperature in neopeptone broth (Difco), were washed twice in phosphate buffer (6.7 mM, pH 7.2) by centrifuging (80 g for 4 min) and left overnight in fresh buffer. In the flat bottomed wells of a micro-titre plate, 0.2 ml volumes of buffered cell suspension (5×10^4 cells/ml) were mixed with 0.2 ml buffered anaesthetic solutions of various dilutions. The lowest concentration (MIC) which completely inhibited motility after 60 min was determined by examining the wells microscopically (160 \times magnification).³⁴

RESULTS

The results of inhibition of *T. pyriformis* mobility test by the test agents and some of their pertinent properties³⁴⁻³⁸ are presented in Table I. MIC and clinical anaesthetic concentration (CAC) are expressed in % W/V. The onset (OA) and duration (DA) of actions are expressed in minutes and the serum half-life (SHL or T $\frac{1}{2}$) in hours, while pKa is the ionisation constant of the test compounds.

Table I. Results of inhibition of *T. pyriformis* mobility test by the assayed compounds and some of their properties

| Compounds | MIC | CAC | OA | DA | t $\frac{1}{2}$ | pka |
|----------------|-------------|---------|------|---------|-----------------|------|
| Lidocaine.HCl | 1.50-2.00 | 0.5-4.0 | 5-10 | 30-90 | 1.6 | 7.86 |
| Prilocaine.HCl | 1.25-1.50 | 1.0-3.0 | 3-10 | 60-120 | -- | 7.86 |
| Etidocaine.HCl | 1.00-1.25 | 0.5-1.5 | 5-15 | 60-150 | 2.7 | 7.74 |
| Amylocaine.HCl | 0.75-1.00 | -- | 5-15 | 90-150 | -- | -- |
| Tetracaine.HCl | 0.175-0.350 | 0.2-1 | 7-15 | 120-180 | -- | 8.39 |

* Figures of MIC are average of three experiments performed in duplicate.

DISCUSSION

A close scrutiny of the results indicates that there is an apparent inverse relationship between the MIC of the test agents on *T. pyriformis* and their duration of actions. MIC was high for the short-acting anaesthetics and low for the long-acting ones while the duration of

action generally increases in the opposite aforementioned order. On the other hand, a positive direct correlation was observed between MIC and CAC of the test compounds, i.e. MIC decreases in the following order; lidocaine > prilocaine > amylocaine > tetracaine.

Affinity for the nerve membrane has been related to DA.³⁹⁻⁴³ In an isolated nerve preparation, the major factors influencing DA are the specific interaction at the active receptor site and nonspecific binding of adjacent tissues.^{40,44} Moreover, the rate of diffusion of a test agent through capillary endothelial cells increases with increasing lipid solubility or partition coefficient (Log P) of the agent. It is also influenced by the volume of the injected anaesthetic solution.^{45,46} It has been found with several long-acting local anaesthetics that an increase in hydrophobicity or Log P is generally associated with increased DA,³⁴⁻³⁶ and it seems that such anaesthetics resist systemic absorption by adsorption to nonspecific acceptor, i.e. membranes or proteins, near the site of action. Furthermore, it is well known that compounds with high Log P exhibit strong affinity to cellular membranes which are lipid or hydrophobic in nature. Thus, a positive correlation between MIC and DA and, in turn, with Log P could indicate that the anaesthetic compounds are presumably dissolving in the lipid portion of the protozoal cell membrane through hydrophobic interactions resulting in membrane fluidization and, subsequently, loss of the ciliary function.

The transport of local anaesthetics to the site of action in the nerve membrane is influenced by their physicochemical properties, e.g. Log P, pKa and surface activity, and the nature of the protein structures of the tissue at the site of application and surrounding the nerve bath, i.e. specific and nonspecific protein-binding.^{47,48} Apparently, a correlation was not observed neither between MIC and pKa nor between MIC and OA. However, it would be worth while to conduct further investigations to find out whether such a correlation exists between MIC and other factors or not.

Finally, this simple, quick and inexpensive microbiological assay appears to be able to discriminate between local anaesthetics of different duration of actions and, therefore, could provide an appropriate basis for screening other potential series of local anaesthetics as well as other clinically useful therapeutic agents, preferably those that possess surface activity. Moreover, additional investigations on a large series of local anaesthetics are required to draw ultimately a statistically valid and concrete general conclusion.

ACKNOWLEDGEMENT

We would like to express our thanks to Dr. A.J. Bailliel, School of Pharmacy and Pharmacology, University of Strathclyde, for his cooperation in this project.

REFERENCES

- 1- Rowan AN, Stratmann, CJ (eds): The use of alternatives in drug research. London: Macmillan press, 43-48, 1980.
- 2- Hunter SH, Holz GG Jr: Lipid requirements of microorganisms. *Ann Rev Microbiol* 16: 189-204, 1962.
- 3- Frank O, Backer H, Ziffer H, et al: Metabolic deficiencies in protozoa induced by thalidomide. *Science* 139:110-111, 1963.
- 4- Foley GE, McCarthy RE, Binns VM, et al: Comparative study of the use of microorganisms in the screening of potential antitumor agents. *Ann N Y Acad Sci* 76: 413-441, 1958.
- 5- Nishie K, Cole RJ, Dorner JW: Inhibitory effects of certain trichothecenes, cyclopiazonic acid and citreoviridin on *Tetrahymena pyriformis*. *In Vitro Toxicol* 2 (4): 239-247, 1988; from *Chem Abst* 111: 226938j, 1989.
- 6- West RA, Barbera PW Jr, Kolar JR, et al: The agar layer method for determining the activity of diverse materials against selected protozoa. *J Protozool* 9: 65, 1962.
- 7- Giese AC (ed): *Photophysiology, Current Topics*, New York: Academic press, Vol 3, 33-64, 1968.
- 8- Arcose JC, Argus, MF, Wolf G (eds): *Chemical Induction of cancer: structural bases and biological mechanisms*. New York: Academic Press, 2nd ed, Vol 1, 447-449, 1968.
- 9- Hull RW: Protozoa and carcinogenic hydrocarbons. *Develop Ind Microbiol* 6: 35-43, 1964.
- 10- Yoshioka Y, Ose Y, Sato T: Testing for the toxicity of chemicals with *Tetrahymena pyriformis*. *Sci Total Environ* 43 (1-2): 149-157, 1985; from *Chem abst* 103: 49229r, 1985.
- 11- Zhaai S, Bai S, Xu W: Use of *Tetrahymena pyriformis* as a toxicological indicator. *Chem abst* 101: 85213 y, 1984.
- 12- Csaba G, Sudar, F, Nagy Su, et al: Localization of hormone receptors in *Tetrahymena*. *Protoplasma* 91(2): 179-189, 1977.
- 13- Csaba G, Nagy Su: Effects of vertebrate hormones on the cyclic AMP level in *Tetrahymena*. *Acta Biol Med Ger* 35 (10): 1399-1401, 1976.
- 14- Jirovec O: Action of some antibiotics on protozoa. *Schweis Z allgem path U Bakt* 14: 653-666, 1951; from *Chem Abstr* 46: 5735b, 1952.
- 15- Conklin KA, Chou Sc: Effects of antimalarial drugs on uptake and incorporation of macromolecular precursors by *Tetrahymena pyriformis*. *J Pharmacol Exp Ther* 180 (1): 158-166, 1972.
- 16- Sanders N, Nathan HA: Protozoa as pharmacological tools: The antihistamines. *J Gen Microbiol* 21: 264-270, 1959.
- 17- Rogers WGG: Effects of phenothiazines on growth, glucose uptake, and cell composition in *Tetrahymena pyriformis*. *Can J Biochem* 44(11): 1493-1503, 1966.
- 18- Chou SC, Ramanathan SH, Conklin KA: Chlorpromazine effects on macromolecular synthesis in synchronized *Tetrahymena*. *Pharmacology* 6(1): 1-8, 1971.
- 19- McLaughlan JM, Shenoy KG, Campbell JA: Some apparant drug- vitamin interrelationships in *Lactobacillus leichmannii* and *Tetrahymena pyriformis*. *J Pharm Sci* 50: 59-63, 1961.
- 20- Holmlund CE: Growth inhibition of *Tetrahymena pyriformis* by a hypocholesteremic compound and the mechanism of its reversal by various lipids. *Biochim Biophys Acta* 296(1): 221-233, 1973.
- 21- Holmlund CE, Bothons N: Growth inhibition of *Tetrahymena pyriformis* by 3- dialkylaminoethoxy steroids. *Life Sci (Oxford)* 5: 2133-2139, 1966.
- 22- Nunn JF, Sturrock JE, Wills EJ, et al: Effects of inhalational anaesthetics on the swimming velocity of *Tetrahymena pyriformis*. *J Cell Sci* 15(3): 537-554, 1974.
- 23- Baker H, Frank O (eds): *Clinical Vitaminology: Methods and Interpretation*. New York: Interscience, PP. 244, 1969.
- 24- Barton-Wright EC(ed): *The microbiological assay of the vitamin B complex and amino acids*. London: lasac Pitman and Sons, PP. 179, 1952.
- 25- Bertoni L: Tissue toxicity of radiological contrast media evaluated with *Tetrahymena pyriformis*. *Experientia* 23(1): 59-60, 1967.
- 26- Mark MF, Imparato AM, Hunter SH, et al: Estimate of toxicity of radiopaque agents by means of a ciliate. *Angiology* 14(8): 383-389, 1963.
- 27- Schultz TW, Dawson DA, Lin DT: Comparative toxiciey of selected nitrogen-containing aromatic compounds in the *Tetrahymena pyriformis* and promelatest systems. *Chemosphere* 18 (11-12): 2283-2291, 1989.
- 28- Florkin M, Scheer BJ(eds): *Chemical Zoology*. New York: Academic Press, Vol 1, 1-20, 1968.
- 29- Schnitzer RJ, Hawking F (eds): *Experimental Chemotherapy*. New York: Academic Press, Vol 1, 657-659, 1967.
- 30- Dessi P: Action of morphine on Hela cell and *Tetrahymena pyriformis* culture growth. *Arch Ital Sci Farmacol* 15(3-4): 172-176, 1965.
- 31- Nandini- Kishore SG, Kitajima Y, Thompson GA Jr: Membrane fluidizing effects of the general anaesthetic methoxyfluorane elicit an acclimation response in *Tetrahymena*. *Biochem Biophys Acta* 471(1): 157-161, 1977.
- 32- Thompson GA Jr, Bambery RJ, Nozawa Y: Membrane formation in *Tetrahymena pyriformis*. Lipid composition and biochemical properties of *Tetrahymena pyriformis* systems. *Biochemistry* 10 (24): 4441-4447, 1971.
- 33- Thompson GA Jr, Nozawa Y: Lipids of Protozoa: Phospholipids and neutral lipids. *Ann Rev Microbiol* 26: 249-278, 1972.
- 34- Al-Saadi D: *Potential Long-Acting Local Anaesthetics*. Ph.D. Thesis. Glasgow: University of Strathclyde, 1981.
- 35- Gennaro AR(ed): *Remington's Pharmaceutical Sciences*. Easton: Mack Publishing Co., 17th edn, 1048-1058, 1985.
- 36- Reynolds JEF (ed): *Martindale: The extra pharmacopoeia*. London: Pharmaceutical press, 29th ed, 1205-1227, 1989.
- 37- Kastrup EK, Boyd JR: *Drug facts and comparisons*. St. Louis: Lippincott, 1975-1985, 1986.
- 38- Darling CM: Local anaesthetic agents. in: Delgado JN, Remers WA (eds): *Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry*. Philadelphia: Lippincott, 9th, ed, 585-602, 1991.
- 39- Adriani J, Maraghi M: The pharmacological principles of regional pain relief. *Ann Rev Pharmacol Toxicol* 17: 223, 1977.
- 40- Rowland M: Local anaesthetic absorption, distribution and elimination. In: Eger EI (ed): *Anesthetic Uptake and Action*. Baltimore: Williams and Wilkins Co, 332-360, 1974.
- 41- Kim JM, Goto H, Arakawa K: Duration of bupivacaine intradermal anaesthesia when the bupivacaine is mixed with chloroprocaine. *Anesth Angala (Cleveland)* 58 (5): 364-366, 1979.
- 42- Covino BG, Vassallo HG: *Local Anesthetics, Mechanisms of Action and Clinical Use*. New York: Grune and Stratton, 1976.
- 43- Ritchie JM, Green NM: Local anaesthetics. In: Gilman AG, Goodman LS, Rall TW, Murad F (eds): *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. New York: Macmillan, 7th ed, Vol 1, 302-321, 1985.
- 44- Wilbrandt W, Cuadra JL et al: Testing local anesthetics on peripheral nerve trunks and the mechanism of potentiation by caffeine. *Helv Physiol Pharmacol Acta* 5: 265-271, 1947.
- 45- Pappenheimer J: Passage of molecules through capillary walls.

Inhibition of Tetra hymena Pyriformis

- Physiol Rev 33: 387-423, 1953.
- 46- Fink BR(ed): Molecular mechanisms of anesthesia. In: Progress in Anesthesiology. New York: Raven Press. Vol 2, 1980.
- 47- Büchi J, Perlia X: The design of local anesthetics. In: Ariens EJ (ed): Drug Design. New York: Academic press. Vol III, 243-391, 1972.
- 48- Büchi J, Perlia X: Structure-activity relations and physico-chemical properties of local anesthetics. In: Lechat P(ed): Int Encycl Pharmacol Ther, Oxford: Pergamon, Vol 1, sec 8, 39-129, 1971.